Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04687059
Other study ID # PQGrass309
Secondary ID 2020-000408-13
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date October 19, 2020
Est. completion date October 28, 2021

Study information

Verified date September 2021
Source Allergy Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting. The study will enrol adult subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis (SAR) induced by grass pollen exposure.


Description:

PQGrass309 is a randomised, double-blind, placebo-controlled exploratory study to explore the efficacy and safety of PQ Grass 27600 SU in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis (SAR) induced by grass pollen exposure. The study is expected to be conducted in the United States (US) and the European Union (EU). The study will enrol enough subjects to allow treatment of approximately 150 subjects. The aim of this exploratory field study is to explore amongst others the following: - The efficacy and safety (up to 6 months following treatment) of a cumulative dose of 27600 standardised units (SU) of PQ Grass in the treatment of grass pollen allergy. - The expected average treatment effect on combined symptom and medication score.


Recruitment information / eligibility

Status Completed
Enrollment 119
Est. completion date October 28, 2021
Est. primary completion date August 18, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Informed Consent 1. Capable of giving signed informed consent and demonstrates willingness to comply with the requirements and restrictions listed in the ICF and study protocol and to attend required study visits. 2. Subject who has signed and dated the ICF. - Age: 3. 18 to 65 years of age inclusive, at the time of signing the ICF. - Sex / Contraceptive requirements: 4. Male or female. 5. Female subjects who are not of childbearing potential (defined as at least 12 months natural spontaneous amenorrhoea, or at least 6 weeks following surgical menopause) or females of childbearing potential who agree to comply with the contraceptive requirements of the study protocol. - Subjects and general health characteristics: 6. Good general health, as determined by the investigator, based on a medical evaluation, including medical history, physical examination, and laboratory tests. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. 7. Positive history of moderate to severe symptoms of seasonal allergic rhinitis and/or rhinoconjunctivitis ascribed to grass (Pooideae) pollen exposure that required repeated use of antihistamines, nasal corticosteroids, and/or leukotriene modifiers for relief of symptoms during the last 2 consecutive seasons prior to the study, confirmed by subject records. Please note: Subjects with asthma may be included, but the asthma must be well controlled (according to current Global Initiative for Asthma {GINA} guidelines [GINA, 2020]). 8. A positive SPT for grass pollen (wheals [longest diameter] =3 mm and histamine =3 mm) and a negative SPT to the negative control (wheal diameter =0) at screening. 9. Grass specific IgE class =2 as documented by an ImmunoCAP test at screening. 10. FEV1 =80% of predicted, with a FEV1/FVC ratio =70% and (PEFR) =75% predicted at screening. 11. Subjects who have no suspicion or symptoms of SARS-CoV-2 infection (as assessed by the investigator) or who have had no contact with a confirmed case of COVID-19 in the past 2 weeks prior to screening and randomisation. Exclusion Criteria (include amongst others): - Medical conditions: 1. Pregnant or lactating subject. 2. Moderate to severe allergy symptoms during the screening and treatment periods, and/or GPS caused by perennial allergens or seasonal allergens (other than grass) as verified by medical history and positive SPT. Exception: screening, treatment and collection of eDiary data can be conducted outside of the pollen season(s) of concern or perennial allergies are irrelevant due to avoidance measures (e.g., cats and dog allergy). 3. Subjects with a positive SPT at US and EU sites in regions with relevant southern grass (Bahia grass, Bermuda grass or Johnson grass) exposure. 4. Moderate to severe symptoms during the 3 years prior to Visit 1 to another seasonal or perennial allergen not tested in the SPT that cannot be avoided during the study and the symptoms of which may interfere with administration of treatment and /or impact the data collected, as determined by the investigator. 5. Presence of any medical condition that may reduce the ability to survive a serious allergic reaction. 6. History of autoimmune disease including Hashimoto's thyroiditis or other immunological disorder or other diseases (including, but not limited to, malignancy, cardiovascular, gastro-intestinal, hepatic, renal, hematological, neurological, endocrine or pulmonary disease) that in the opinion of the investigator may pose a safety risk or compromise the interpretation of efficacy of the study treatment. 7. Presence of severe or uncontrolled or partly controlled asthma as defined in the GINA guidelines (GINA 2020) or asthma that requires more than a daily dose above 400 mcg of inhaled budesonide or equivalent. 8. Emergency room visit or hospitalisation for asthma in the 12 months prior to screening and randomisation or any history of a life-threatening asthma attack. 9. Presence of non-atopic rhinitis and/or rhino-sinusitis (with or without polyps). 10. Presence of nasal polyps and/or chronic sinusitis. 11. Presence of any acute or chronic ocular disorder, other than allergic conjunctivitis, which could interfere with the evaluation of CPT. 12. Eye surgery within the past 6 months. 13. Presence of any skin conditions (e.g. skin abnormalities, tattoos) which might interfere with the interpretation of the SPT results. 14. Clinical history of Type I diabetes. Subjects with well-controlled Type II diabetes will be allowed to participate at the discretion of the investigator. 15. Any acute infection (including upper respiratory tract infections in the 14 days prior to Visit 2), which in the opinion of the investigator may pose a safety risk to the subject. 16. Clinical history of severe or serious systemic reaction in response to AIT treatment in the past. 17. Clinical history of severe or life-threatening anaphylactic reactions to foods, insect venom, exercise, drugs or idiopathic anaphylaxis. 18. Clinical history of allergy, hypersensitivity or intolerance to the excipients of the IMP. 19. Tyrosine metabolism disorders, especially tyrosinemia and alkaptonuria. - Prior/concomitant therapy: 20. History of any allergen SIT. 21. Inability to adhere to the washout periods for Prohibited Medications/Therapies with respect to Visit 1/1a and to refrain from using the medications indicated until after Visit 15. 22. Treatment with a preparation containing MPL (e.g., Cervarix, Shingrix, Fendrix) within 2 years prior to Visit 1 and until after completion of Visit 15 (with the exception of the IMP). 23. Unable to receive epinephrine therapy (i.e., use of epinephrine is contraindicated such as in subjects with hyperthyroidism, uncontrolled hypertension, cardiac arrhythmias, closed angle glaucoma or subjects taking other sympathomimetic). 24. Previous history of epinephrine device use. 25. ß-blocker medication (including eye drops), for any indication. 26. Monoamine oxidase inhibitors and tricyclic antidepressants. (Tricyclic antidepressants should be avoided at least 2 weeks prior to screening). 27. Any previous therapy (within 12 months prior to screening) or current therapy with anti IgE (e.g., Xolair) or anti-interleukins (e.g., mepolizumab) or any other therapy with a biologic agent. 28. Unable to refrain from any vaccination (including influenza and any potential vaccine for COVID-19) during the study (unless administered more than 30 days prior to randomisation). Please note: Emergency vaccinations (e.g., tetanus due to injury) can be administered at any time. 29. Current or past therapy (within the previous 5 years) with immunosuppressant drugs or immunomodulatory biologics. Other exclusions 30. Clinical history of drug or alcohol abuse which, in the investigator's opinion, could interfere with the subject's ability to participate in the study. 31. Participation in a clinical research trial with any IMP within 4 weeks of Visit 1 or concomitantly with this study 32. Personal, financial or other dependent relationship (e.g., employee or immediate relative) with the study site, Sponsor, Sponsor's representative, or another individual who has access to the study protocol. 33. Vulnerable subjects or those in judicial or governmental detention, detainment or imprisonment in a public institution. 34. Subjects likely to have prolonged periods of absence (e.g., business or personal travel) during the GPS defined as: - Absence of 22 days or more in similar or mixed geographic regions as determined by the investigator, with no single trip in a similar geographical region exceeding 14 days and no single trip in a non-similar geographical region exceeding 7 days, - Absence of 15 days or more in non-similar geographic regions as determined by the investigator, with no single trip exceeding 7 days. 35. Have changed residence between geographical regions since the last GPS. Exception: the old and new residences are in the same or similar geographical region as determined by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
PQ Grass
Suspension for injection
Drug:
Placebo Option 1
Suspension for injection
Placebo Option 2
Solution for injection

Locations

Country Name City State
Germany Universitatsmedizin Berlin - Charite Campus Mitte - Allergie Centrum Charite Berlin
Germany Universitätsklinikum Carl Gustav Carus an der TU Dresden Dresden
Germany ENT RESEARCH - Institut für klinische Studien Essen
Germany Medaimun GmbH Frankfurt am Main
Germany Hamburger Institut für Therapieforschung GmbH Hamburg
Germany Studienzentrum Dr. Sabine Laßmann Saalfeld
United States Allergy Partners of Western North Carolina Asheville North Carolina
United States Bernstein Clinical Research Center, LLC Cincinnati Ohio
United States Smith Allergy & Asthma Specialists Cortland New York
United States Allergy Asthma & Sinus Center, S.C. Greenfield Wisconsin
United States Corning Center for Clinical Research Horseheads New York
United States Allergy and Asthma Associates of Bluegrass Lexington Kentucky
United States Atlantic Research Center, LLC Ocean Township New Jersey
United States Chesapeake Clinical Research, Inc. White Marsh Maryland

Sponsors (1)

Lead Sponsor Collaborator
Allergy Therapeutics

Countries where clinical trial is conducted

United States,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary CSMS (Combined symptom and medication score) averaged over the peak grass pollen season (GPS) 6 individual symptoms assessed in a 4 point severity scale (0-No symptoms to 3-Severe symptoms Approximately 2-5 weeks
Secondary CSMS averaged over the entire (or truncated) GPS 6 individual symptoms assessed in a 4 point severity scale (0-No symptoms to 3-Severe symptoms) Approximately 10 weeks
Secondary Total combined score (TCS) averaged over the peak GPS 6 individual symptoms in a similar fashion to CSMS assessed in a 4 point severity scale (0-No symptoms to 3-Severe symptoms) Approximately 2-5 weeks
Secondary TCS averaged over entire (or truncated) GPS 6 individual symptoms in a similar fashion to CSMS assessed in a 4 point severity scale (0-No symptoms to 3-Severe symptoms) Approximately 10 weeks
Secondary Daily symptom score (dSS) of the CSMS averaged over the peak and entire (or truncated) GPS Sum of the scores (0-No symptoms to 3-Severe symptoms) for the 6 individual symptoms assessed in CSMS divided by 6 Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS
Secondary Daily medication score (dMS) of the CSMS averaged over the peak and entire (or truncated) GPS Score 0 (no relief medication) to 3 (highest step relief medication) per day; based on at least 1 dose of the medication of the highest step taken that day Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS
Secondary dSS of the TCS averaged over the peak GPS and entire (or truncated) GPS Sum of the scores (0-No symptoms to 3-Severe symptoms) for the 6 individual symptoms (i.e. ranging from 0 to 18) Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS
Secondary dMS of the TCS averaged over the peak GPS and entire (or truncated) GPS Score 0 (no relief medication) to 3 (highest step relief medication) per day; based on at least 1 dose of the medication of the highest step taken that day Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS
Secondary TSS during CPT, CSMS, TCS, dSS (for CSMS and TCS) and dMS (for CSMS and TCS) over the peak and entire (or truncated) GPS for subjects with a positive CPT at baseline. CPT - Conjunctival provocation test - At screening, during randomization and pre-GPS Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS
Secondary The probability of well days and severe days during the peak and entire (or truncated) GPS. Approximately 10 weeks. Duration of the Peak Grass pollen season (GPS) to be determined as per pollen counts within the GPS
Secondary Pre-GPS (Visit 12) TSS measured during CPT Pre-season Assessment Baseline (pre-GPS)
Secondary Serum Ig responses (total IgE; grass-specific IgE and IgG4; specific IgE/total IgE and specific IgE/specific IgG4) at Visit 12 and Visit 15. Approximately 10 weeks
Secondary RQLQ(S) measured within the GPS Rhinoconjunctivitis quality of life questionnaire with standardised activities - RQLQ(S) Approximately 10 weeks
Secondary Frequency, severity and relationship of AEs to treatment AEs - Adverse Events Up to 1 year
Secondary Frequency of AEs leading to premature discontinuation from treatment or study Up to 1 year
Secondary Frequency of AESI AESI - Adverse events of special interest Up to 1 year
Secondary Changes in serum chemistry values between screening and Visit 15 Including sodium, potassium and chloride concentration 6 months approximately
Secondary Changes in serum chemistry values between screening and Visit 15 Including Glucose, uric acid, urea, calcium, creatinine, total protein, phosphorus, cholesterol, albumin and total bilirubin concentration 6 months approximately
Secondary Changes in serum chemistry values between screening and Visit 15 Including alkaline phosphatase, LDH, AST, ALT, GGT, CRP. 6 months approximately
Secondary Changes in haematology values between screening and Visit 15 - RBC, WBC, Platelets Including total WBC and differentials, total RBC, RBC indices and platelet count. 6 months approximately
Secondary Changes in haematology values between screening and Visit 15 - Haemoglobin Haemoglobin concentration 6 months approximately
Secondary Changes in clinical laboratory values (urinalysis) between screening and Visit 15 Urinalysis (using a urine dip-stick) pH, protein, glucose, ketones, bilirubin, blood, nitrite, urobilinogen, leukocytes.
Note: Microscopic examination will be conducted if protein, leukocytes, nitrite, and/or blood are detected. If needed, microscopic examination will include WBC, RBC, casts, and bacteria.
6 months approximately
Secondary Changes in vital signs (all subjects) at all treatment visits - Blood pressure systolic and diastolic blood pressure 7 months approximately
Secondary Changes in vital signs (all subjects) at all treatment visits - Pulse rate 7 months approximately
Secondary Changes in vital signs (all subjects) at all treatment visits - Respiratory rate 7 months approximately
Secondary Changes in vital signs (all subjects) at all treatment visits - Body temperature 7 months approximately
Secondary Changes in PEFR (only in subjects with past or current asthma) at all treatment visits PEFR - peak expiratory flow rate 7 months approximately
See also
  Status Clinical Trial Phase
Terminated NCT01337323 - Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting N/A
Completed NCT00851344 - Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo Phase 2
Completed NCT00501527 - Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense Phase 2
Completed NCT00537355 - An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber Phase 2
Completed NCT00422149 - Twin SUBLIVAC® Grasses Clinical Efficacy Study Phase 3
Completed NCT00542607 - Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis Phase 4
Completed NCT00605852 - Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects Phase 1
Active, not recruiting NCT05960266 - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study Early Phase 1
Completed NCT02256553 - Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) Phase 4
Completed NCT00932256 - Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients Phase 1
Completed NCT01007721 - Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season Phase 2
Completed NCT00901914 - Study of rBet v1 Tablets Phase 2
Completed NCT00384475 - A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413) Phase 3
Completed NCT00839189 - Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults Phase 1
Completed NCT00135629 - Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever Phase 3
Completed NCT00889460 - Safety and Tolerability Study of rBet v1 SLIT Tablets Phase 1
Completed NCT00396149 - Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1 Phase 1
Completed NCT00659594 - Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406) Phase 3
Completed NCT00127647 - An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327) Phase 3
Completed NCT01480271 - An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics. Phase 1